en
svBulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026
The following resolutions were passed at the annual general meeting (the “AGM”) of Xspray Pharma AB (publ) (“Xspray”) on 12 May 2026. Adoption of income statement and balance sheet for the financial year 2025 and discharge from liabilityThe AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2025 […]
Read moreNew number of shares and votes in Xspray Pharma after new share issue April 2026
Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces that the number of shares and votes in Xspray Pharma AB has changed. New shares have been issued as a result of the rights issue and over-allotment issue announced on March 24, 2026. On March 26, 2026, the Board of Directors also decided to increase the over-allotment […]
Read moreInterim Report First Quarter 2026
January–March 2026, Group Net sales amounted to SEK 0 thousand (0) Earnings before tax amounted to SEK -35,380 thousand (-42,321) Earnings per share before dilution amounted to SEK -0.85 (-1.14) Cash flow from operating activities amounted to SEK -30,676 thousand (-66,329) Cash flow from investing activities amounted to SEK -1,067 thousand (-14,701) Amounts in parentheses […]
Read moreXspray’s rights issue oversubscribed – over-allotment issue fully utilized
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL […]
Read moreFDA accepts trade name Nilopki® for Xspray’s drug candidate XS003 (nilotinib)
The US Food and Drug Administration (FDA) has accepted Nilopki® as the proprietary name for Xspray Pharma's drug candidate XS003 (nilotinib). Nilopki is an improved, amorphous formulation of nilotinib (Tasigna®) for the treatment of chronic myeloid leukemia (CML), developed on Xspray's proprietary HyNap™ platform. Upon market approval, Xspray plans to launch Nilopki® in the US […]
Read moreNotice of annual general meeting of Xspray Pharma AB (publ)
The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, (”Xspray Pharma”) are summoned to the annual general meeting on Tuesday 12 May 2026 at 10.00 CEST at Advokatfirman Vinge’s office on Smålandsgatan 20 in Stockholm. Registration starts at 9.30 CEST. The shareholders may exercise their voting rights at the annual general meeting by attending […]
Read moreXspray publishes disclosure document regarding rights issue
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL […]
Read moreXspray receives additional subscription undertakings; rights issue now covered to 110% and over-allotment issue increased
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL […]
Read moreXspray Pharma publishes its Annual Report 2025
Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today publishes its Annual Report for the financial year 2025. An extract from the CEO-letter from Per Andersson, CEO of Xspray Pharma:“In 2025, Xspray took several decisive steps on our journey to becoming a commercial pharmaceutical company. While we cannot yet determine the outcome of the ongoing regulatory processes, […]
Read moreXspray resolves on a rights issue of approximately SEK 83 million with an over-allotment issue
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL […]
Read more